Pediatrix Medical Group (MD) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenue was $458.4 million, down 7.4% year-over-year due to practice dispositions, but same-unit revenue grew over 6% and net income rose to $20.7 million from $4.0 million, driven by margin improvement and cost management.

• Adjusted EBITDA increased to $49.2 million from $37.2 million year-over-year, reflecting strong same-unit results and practice optimization.

• Strategic focus on hospital-based and maternal-fetal medicine services, with completed exit from most office-based practices and new contracts for NICU, MFM, and OB hospital operations.

• Portfolio restructuring and cost management led to improved margins and lower operating expenses.

• Same-unit revenue growth was driven by favorable payor mix, increased administrative fees, and higher hospital-based service volumes, particularly NICU days up 2%.

Financial highlights

• Adjusted EBITDA for Q1 2025 was $49.2 million, significantly above expectations and up from $37.2 million year-over-year.

• Same-unit net revenue grew by $26.1 million (6.2%), with pricing up 4.6% year-over-year due to favorable payer mix and contract fee improvements.

• Practice salaries and benefits expense fell to $337 million from $369 million year-over-year.

• Operating margin improved to 7.0% from 3.2% year-over-year; excluding restructuring, margin was 8.4%.

• Cash and cash equivalents were $99 million at March 31, 2025, down from $230 million at year-end 2024.

Outlook and guidance

• Full-year 2025 adjusted EBITDA outlook raised to $220 million–$240 million from $215 million–$235 million.

• Guidance remains conservative due to ongoing economic and healthcare sector uncertainty, with tougher comps expected for the remainder of 2025.

• Management expects funds from operations, cash on hand, and available credit to be sufficient for working capital, acquisitions, capital expenditures, and share repurchases for at least the next 12 months.

• The company anticipates continued compliance with all debt covenants throughout 2025.

• No anticipated changes in seasonality or payer mix trends for 2025.